Will Tomorrow's CAR-T Therapy Innovations Solve Today's Challenges?

Sharon Karlsberg, Principal, Oncology, ZS Associates, considers the future of CAR-T therapies with Michael R. Bishop, MD, Professor of Medicine, Director, Hematopoietic Stem Cell Transplantation Program, University of Chicago.

Sharon Karlsberg, Principal, Oncology, ZS Associates, considers the future of CAR-T therapies with Michael R. Bishop, MD, Professor of Medicine, ...

How Can Manufacturers Help Institutions Prepare for CAR-T Therapies?

Sharon Karlsberg, Principal, Oncology, ZS Associates, considers how manufacturers can help institutions prepare for CAR-T therapies with Michael R. Bishop, MD, Professor of Medicine, Director, Hematopoietic Stem Cell Transplantation Program, University of Chicago.

Sharon Karlsberg, Principal, Oncology, ZS Associates, considers how manufacturers can help institutions prepare for CAR-T therapies with Michael R. Bishop, ...

How Can a CAR-T Center Get Established and Effectively Treat Patients?

Sharon Karlsberg, Principal, Oncology, ZS Associates, discusses how a CAR-T center becomes established and effectively treats patients with Michael R. Bishop, MD, Professor of Medicine, Director, Hematopoietic Stem Cell Transplantation Program, University of Chicago.

Sharon Karlsberg, Principal, Oncology, ZS Associates, discusses how a CAR-T center becomes established and effectively treats patients with Michael R. ...

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

Dr. Ou considers whether Tumor Mutation Burden (TMB) is a valid biomarker in determining non-small cell lung cancer (NSCLC) patients likely to benefit from immunotherapy

Dr. Ou considers whether Tumor Mutation Burden (TMB) is a valid biomarker in determining non-small cell lung cancer (NSCLC) patients ...

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

Dr. Ou provides opinion on whether he would continue pemetrexed maintenance after successful treatment of a patient with carboplatin, pemetrexed, and pembrolizumab

Dr. Ou provides opinion on whether he would continue pemetrexed maintenance after successful treatment of a patient with carboplatin, pemetrexed, ...

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

Dr. Ou elaborates on the key takeaways from the IMpower150 study in non-small cell lung cancer (NSCLC) and whether the outcomes change how we treat post-EGFR patients

Dr. Ou elaborates on the key takeaways from the IMpower150 study in non-small cell lung cancer (NSCLC) and whether the ...

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

Dr. Ou offers opinion on how chemotherapy should be combined with immunotherapy in the treatment of 2nd line non-small cell lung cancer (NSCLC)

Dr. Ou offers opinion on how chemotherapy should be combined with immunotherapy in the treatment of 2nd line non-small cell ...

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

Dr. Ou discusses outcomes from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in the treatment of 1st line non-small cell lung cancer (NSCLC)

Dr. Ou discusses outcomes from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in the treatment of 1st ...

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

Dr. Ou offers opinion on whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and what levels of PD-L1 expression are actionable

Dr. Ou offers opinion on whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and ...

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

Dr. Levy elaborates on whether Tumor Mutation Burden (TMB) is a valid biomarker to determine those non-small cell lung cancer (NSCLC) patients likely to benefit from immunotherapy

Dr. Levy elaborates on whether Tumor Mutation Burden (TMB) is a valid biomarker to determine those non-small cell lung cancer ...